|
Sign In to gain access to subscriptions and/or personal tools.
|
Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes
John R Petrie
Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK, johnp{at}memo.dundee.ac.uk
Mike Kirby
The Hertfordshire Primary Care Research Network The Nevells Road Surgery, Nevells Road, Letchworth, Herts, SG6 4TS, UK
References
- He F., MacGregor G. Cost of poor blood pressure in the UK: 62,000 unnecessary deaths per year. J Hum Hypertens 2003;17:455-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Health Survey for England: Cardiovascular Disease. 1999. The Stationery Office London.
- Morris AD Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev 2002;18 (suppl 3):S32-S35.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Investing in General Practice. The New General Medical Services Contract. BMA, February 2003 (see also www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/PrimaryCare/PrimaryCareContracting/fs/en accessed 6th October 2004).
- Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-52.[Abstract/Free Full Text]
- Guidelines Committee. 2003 European Society for Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
- Williams B., Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- North of England Hypertension Guideline Development Group. Essential hypertension: managing adults in primary care. Centre for Health Services Research Report No 111, University of Newcastle on Tyne, 2004 (www.nice.org.uk/pdf/CG018fullguideline.pdf. Accessed 6th October 2004).
- Law MR, Wald NJ, Morris JK, Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427-31.[Abstract/Free Full Text]
- Ramsay LE, Williams B., Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 2003;13:569-92.[CrossRef]
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Colhoun HM, Betteridge DJ, Durrington P. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Staessen JA, Wang J-G., Thijs L. Cardiovascular Prevention and blood pressure reduction a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-76.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Julius S., Kjelsen SE, Brunner H. et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J S Hypertens 2003;16:544-8.[CrossRef]
- Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McInnes GT `Size is not everything:' the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT). Br J Diabetes Vasc Dis 2003;3:263-7.[Abstract/Free Full Text]
- The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Svensson P., de Faire U., Sleight P. et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:e28-e32.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Padwal R., Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004;27:247-55.[Abstract/Free Full Text]
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-20.[Abstract/Free Full Text]
- Fretheim A. VALUE: analysis of results (letter). Lancet 2004;364:934-5.[Medline]
[Order article via Infotrieve]
- CS Lewis. That Hideous Strength (1945). London, Harper Collins (Paperback edition, 2000).
The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6,
365-368 (2004)
DOI: 10.1177/14746514040040060101

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Kirby
Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents?
The British Journal of Diabetes & Vascular Disease,
March 1, 2005;
5(2):
100 - 102.
[Abstract]
[PDF]
|
 |
|
|
|